Longitudinal Evaluation and Real-world Evidence of NT201

Stopped early

Conditions studied: Glabellar Frown Lines and Canthal Lines and/or Horizontal Forehead Lines in the Upper Face

In brief

This study is to collect long-term real-world evidence data from clinics in several countries in order to obtain an improved understanding of the safety and effectiveness of incobotulinumtoxinA in botulinum neurotoxin type A (BoNT-A) treatment naïve participants.

Key facts

Study ID

NCT05222607

Run by

Merz North America, Inc.

People needed

11

Starts

2023-02-10

Expected to finish

2023-05-18

Last updated by the study team

2023-06-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years of age or older.
• Planning treatment with incobotulinumtoxinA.

You may not qualify if…

• Any contraindication to treatment with incobotulinumtoxinA or any other neurotoxins.
• Currently pregnant, breastfeeding, or intending to become pregnant during study participation.
• Known hypersensitivity to incobotulinumtoxinA or any of its formulation ingredients.
• Any infection and/or inflammation at the planned injection points.
• Previous treatment with any botulinum toxin products for any aesthetic or therapeutic indications.

Where it is running

• SkinDC — Arlington, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.